137 related articles for article (PubMed ID: 16258942)
1. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease.
Dubinsky R; Gray C
Mov Disord; 2006 Apr; 21(4):530-3. PubMed ID: 16258942
[TBL] [Abstract][Full Text] [Related]
2. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
[TBL] [Abstract][Full Text] [Related]
3. A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease.
Prundean A; Youssov K; Humbert S; Bonneau D; Verny C
Mov Disord; 2015 Feb; 30(2):288-9. PubMed ID: 25475049
[No Abstract] [Full Text] [Related]
4. Assessment of coenzyme Q10 tolerability in Huntington's disease.
Feigin A; Kieburtz K; Como P; Hickey C; Claude K; Abwender D; Zimmerman C; Steinberg K; Shoulson I
Mov Disord; 1996 May; 11(3):321-3. PubMed ID: 8723151
[TBL] [Abstract][Full Text] [Related]
5. Sodium phenylbutyrate in Huntington's disease: a dose-finding study.
Hogarth P; Lovrecic L; Krainc D
Mov Disord; 2007 Oct; 22(13):1962-4. PubMed ID: 17702032
[TBL] [Abstract][Full Text] [Related]
6. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
Gibrat C; Cicchetti F
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):380-9. PubMed ID: 21111020
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cystinosis with cysteamine. A pilot study determining dose and form of application.
Bergonzi E; Herren A; Lavanchy P; Bühlmann C; Wyss SR; Lüthy C; Oetliker O
Helv Paediatr Acta; 1981 Nov; 36(5):437-43. PubMed ID: 7031022
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.
; Hyson HC; Kieburtz K; Shoulson I; McDermott M; Ravina B; de Blieck EA; Cudkowicz ME; Ferrante RJ; Como P; Frank S; Zimmerman C; Cudkowicz ME; Ferrante K; Newhall K; Jennings D; Kelsey T; Walker F; Hunt V; Daigneault S; Goldstein M; Weber J; Watts A; Beal MF; Browne SE; Metakis LJ
Mov Disord; 2010 Sep; 25(12):1924-8. PubMed ID: 20669312
[TBL] [Abstract][Full Text] [Related]
9. [Cysteamine restores intracellular dynamics and BDNF secretion in Huntington's disease].
Saudou F; Humbert S
Med Sci (Paris); 2006 Nov; 22(11):906-8. PubMed ID: 17101082
[No Abstract] [Full Text] [Related]
10. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
Kenney C; Hunter C; Davidson A; Jankovic J
Mov Disord; 2007 Jan; 22(1):10-3. PubMed ID: 17078062
[TBL] [Abstract][Full Text] [Related]
11. Huntington's disease: clinical and chemical effects of choline administration.
Growdon JH; Cohen EL; Wurtman RJ
Ann Neurol; 1977 May; 1(5):418-22. PubMed ID: 152596
[TBL] [Abstract][Full Text] [Related]
12. Capillary electrophoresis method development for determination of impurities in sodium cysteamine phosphate samples.
Carvalho AZ; Pauwels J; De Greef B; Vynckier AK; Yuqi W; Hoogmartens J; Van Schepdael A
J Pharm Biomed Anal; 2006 Sep; 42(1):120-5. PubMed ID: 16413736
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
[TBL] [Abstract][Full Text] [Related]
14. Cysteamine-related agents could be potential antidepressants through increasing central BDNF levels.
Tsai SJ
Med Hypotheses; 2006; 67(5):1185-8. PubMed ID: 16797865
[TBL] [Abstract][Full Text] [Related]
15. Cysteamine: new preparation. Chronic treatment of cystinosis.
Prescrire Int; 1999 Jun; 8(41):67-70. PubMed ID: 10558441
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.
Saft C; Lauter T; Kraus PH; Przuntek H; Andrich JE
BMC Neurol; 2006 Feb; 6():11. PubMed ID: 16507108
[TBL] [Abstract][Full Text] [Related]
17. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
[TBL] [Abstract][Full Text] [Related]
18. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
19. Complex movement behaviour and progression of Huntington's disease.
Andrich J; Saft C; Ostholt N; Müller T
Neurosci Lett; 2007 Apr; 416(3):272-4. PubMed ID: 17321683
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
